Citigroup’s Elicio Therapeutics ELTX Stock Holding History

Citigroup’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.3K	Buy	+17,726	New	+$178K	﹤0.01%	4864
2025 Q4	–	Sell	-10,658	Closed	-$117K	–	6160
2025 Q3	$117K	Buy	+10,658	New	+$108K	﹤0.01%	4205
2025 Q1	–	Sell	-374	Closed	-$1.83K	–	5685
2024 Q4	$1.83K	Hold	374	–	–	﹤0.01%	5553
2024 Q3	$1.88K	Hold	374	–	–	﹤0.01%	5419
2024 Q2	$1.54K	Hold	374	–	–	﹤0.01%	5350
2024 Q1	$2.84K	Hold	374	–	–	﹤0.01%	5366
2023 Q4	$3.12K	Hold	374	–	–	﹤0.01%	5378
2023 Q3	$3.16K	Hold	374	–	–	﹤0.01%	4844
2023 Q2	$3.55K	Hold	374	–	–	﹤0.01%	5223
2023 Q1	$2.17K	Hold	374	–	–	﹤0.01%	5084
2022 Q4	$3.04K	Hold	374	–	–	﹤0.01%	5142
2022 Q3	$3K	Sell	374 -17	-4%	-$178	﹤0.01%	5376
2022 Q2	$4K	Sell	391 -405	-51%	-$6.47K	﹤0.01%	5671
2022 Q1	$17K	Sell	796 -135	-15%	-$3.05K	﹤0.01%	5242
2021 Q4	$27K	Buy	931 +683	+275%	+$34.5K	﹤0.01%	5305
2021 Q3	$24K	Buy	248 +220	+786%	+$23.8K	﹤0.01%	5152
2021 Q2	$4K	Sell	28 -11	-28%	-$1.59K	﹤0.01%	5870
2021 Q1	$7K	Buy	+39	New	+$7.53K	﹤0.01%	5800

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Citigroup's ELTX Position: Q2 2026 in Review

Citigroup opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 17,726 shares worth $69.3K. The stake represents ﹤0.01% of the portfolio and ranks #4864 among its holdings. This is a return to the name: Citigroup previously reported a position in ELTX as recently as Q3 2025.

Citigroup first reported a position in ELTX in Q1 2021 and has held it in 18 quarters since. The position peaked at $117K in Q3 2025. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Citigroup held 17,726 shares of Elicio Therapeutics worth $69.3K as of Q2 2026.
Elicio Therapeutics was a new Citigroup position in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4864 holding.
Citigroup first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 18 quarters since.
Citigroup's Elicio Therapeutics position peaked at $117K in Q3 2025.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.